Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetic contribution to variable human CYP3A-mediated metabolism.

Jatinder K Lamba1, Yvonne S Lin, Erin G Schuetz

  • 1St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

Advanced Drug Delivery Reviews
|October 31, 2002
PubMed
Summary

Genetic variations in human CYP3A enzymes influence drug metabolism and disease risk. Polymorphic expression of CYP3A5 and CYP3A7, alongside environmental factors, contributes to inter-individual differences in drug response.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ToxBase: A Multidimensional ToxCast Reference Database for High-Throughput Human Exposome Analysis.

Environmental science & technology·2026
Same author

IMFrag: A Tool to Recognize In-Source Fragmentation in Ion Mobility-Enabled Data-Independent Acquisition Workflows.

Analytical chemistry·2026
Same author

Impact of the gut microbiome on hepatic cytochrome P450 3A4 (CYP3A4) in humanized pregnane X receptor-constitutive androstane receptor-CYP3A4/3A7 mice.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Interstitial loss of heterozygosity at Chr19q13 in CD33-negative AML.

Leukemia·2026
Same author

Semi-Physiological Population Pharmacokinetic Modeling of Oral and Intravenous Paracetamol to Quantify Presystemic Metabolism and Enterohepatic Recirculation.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio.

Clinical pharmacology and therapeutics·2026

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Enzyme Kinetics

Background:

  • The CYP3A subfamily is crucial for drug metabolism, primarily in the liver and small intestine, impacting first-pass and systemic drug elimination.
  • Significant inter-individual variability (up to 40-fold) in CYP3A expression exists, influenced by genetic mutations, environmental factors, and disease states.
  • Understanding genetic variations in CYP3A enzymes is key to explaining differences in drug efficacy and safety.

Purpose of the Study:

  • To review the current understanding of genetic variations within the human CYP3A subfamily.
  • To explore the implications of these genetic variations on drug disposition, efficacy, and safety.
  • To highlight the roles of CYP3A4, CYP3A5, and CYP3A7 genetic polymorphisms.

Main Methods:

Related Experiment Videos

  • Review of existing literature on CYP3A genetic variations, including single nucleotide polymorphisms (SNPs) and their functional consequences.
  • Analysis of allele frequencies and linkage disequilibrium for key CYP3A variants like CYP3A4*1B and CYP3A5*3.
  • Discussion of the impact of polymorphic expression of CYP3A5 and CYP3A7 on drug metabolism and disease association.

Main Results:

  • CYP3A4 exhibits numerous SNPs, but coding variants are rare and unlikely to be the primary cause of clearance variability.
  • CYP3A5 is polymorphically expressed, with the CYP3A5*3 allele significantly reducing protein expression and catalytic activity, particularly in Caucasians.
  • CYP3A7, the fetal isoform, shows altered expression in adults linked to specific promoter mutations (CYP3A7*1C), potentially influencing drug metabolism.

Conclusions:

  • Genetic variations in CYP3A5 and CYP3A7 contribute significantly to inter-individual differences in drug metabolism.
  • The polymorphic expression of CYP3A5, especially its role as an extrahepatic isoform, has implications for disease risk and xenobiotic metabolism.
  • Complex interactions between genetic factors, environmental influences, and regulatory pathways necessitate further research to fully understand CYP3A's role in drug response.